Triple agonists like retatrutide—targeting GLP-1, GIP, and glucagon receptors—have achieved up to 24.2% weight loss in adults (12-mg group), signaling a new generation of anti-obesity pharmacotherapy [41]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.